MedTrace Logo

Study of ECC4703 With Sulfasalazine and Pitavastatin

NCT07726368 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-07-28

No results posted yet for this study

Summary

Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by increased liver fat content, inflammation, and progressive fibrosis. The overall prevalence of non-alcoholic fatty liver disease is rapidly rising world-wide.

ECC4703 is a potential new treatment for non-alcoholic fatty liver disease.

The purpose of this research is to investigate the safety, tolerability and pharmacokinetics of sulfasalazine and pitavastatin when combined with ECC4703.

Conditions

  • Non-alcoholic Fatty Liver Disease (NAFLD)
  • Dyslipidaemia

Interventions

DRUG

ECC4703

ECC4703 will be administered orally.

DRUG

Sulfasalazine

Sulfasalazine will be administered orally.

DRUG

Pitavastatin

Pitavastatin will be administered orally.

Sponsors & Collaborators

  • Eccogene

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07726368 on ClinicalTrials.gov